OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial

OcuTerra Therapeutics, a clinical-stage ophthalmology company, announced the successful full enrollment in its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial. The trial ... Read More